Autologous transplantation therapy for chronic myelogenous leukemia.
Bhatia
R
R
Department of Medicine, University of Minnesota, Minneapolis 55455, USA.
Verfaillie
C M
CM
Miller
J S
JS
McGlave
P B
PB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012008:Recurrence; D016019:Survival Analysis
D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D016898:Interferon-alpha; D016376:Oligonucleotides, Antisense; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl